Rainer F Storb

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6866172/publications.pdf

Version: 2024-02-01

264 papers	39,756 citations	8181 76 h-index	2571 195 g-index
267 all docs	267 docs citations	267 times ranked	14976 citing authors

#	Article	IF	Citations
1	Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 2005, 106, 2912-2919.	1.4	2,427
2	Chronic graft-versus-host syndrome in man. American Journal of Medicine, 1980, 69, 204-217.	1.5	2,369
3	Bone-Marrow Transplantation. New England Journal of Medicine, 1975, 292, 832-843.	27.0	1,635
4	Evidence for Circulating Bone Marrow-Derived Endothelial Cells. Blood, 1998, 92, 362-367.	1.4	1,582
5	HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2008, 14, 641-650.	2.0	1,525
6	Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts. New England Journal of Medicine, 1979, 300, 1068-1073.	27.0	1,431
7	Bone-Marrow Transplantation. New England Journal of Medicine, 1975, 292, 895-902.	27.0	1,360
8	Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia. New England Journal of Medicine, 1986, 314, 729-735.	27.0	1,353
9	Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. New England Journal of Medicine, 2010, 363, 2091-2101.	27.0	1,335
10	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood, 2001, 97, 3390-3400.	1.4	1,306
11	Antileukemic Effect of Chronic Graft-versus-Host Disease. New England Journal of Medicine, 1981, 304, 1529-1533.	27.0	1,049
12	Solid Cancers after Bone Marrow Transplantation. New England Journal of Medicine, 1997, 336, 897-904.	27.0	914
13	Transplantation of Bone Marrow as Compared with Peripheral-Blood Cells from HLA-Identical Relatives in Patients with Hematologic Cancers. New England Journal of Medicine, 2001, 344, 175-181.	27.0	905
14	Marrow Transplantation from Related Donors Other Than HLA-Identical Siblings. New England Journal of Medicine, 1985, 313, 765-771.	27.0	786
15	Stable Mixed Hematopoietic Chimerism in DLA-Identical Littermate Dogs Given Sublethal Total Body Irradiation Before and Pharmacological Immunosuppression After Marrow Transplantation. Blood, 1997, 89, 3048-3054.	1.4	584
16	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood, 2011, 117, 3214-3219.	1.4	544
17	Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood, 2003, 102, 756-762.	1.4	531
18	A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. New England Journal of Medicine, 2007, 356, 1110-1120.	27.0	479

#	Article	IF	Citations
19	Graft-versus-Host Disease and Survival in Patients with Aplastic Anemia Treated by Marrow Grafts from HLA-Identical Siblings. New England Journal of Medicine, 1983, 308, 302-307.	27.0	444
20	Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood, 2003, 101, 1620-1629.	1.4	424
21	Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood, 2002, 100, 415-419.	1.4	403
22	Secondary Cancers after Bone Marrow Transplantation for Leukemia or Aplastic Anemia. New England Journal of Medicine, 1989, 321, 784-789.	27.0	401
23	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood, 2003, 102, 3447-3454.	1.4	382
24	Comorbidity and Disease Statusâ€“Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2007, 25, 4246-4254.	1.6	380
25	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2014, 32, 3249-3256.	1.6	361
26	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. Blood, 1997, 89, 4226-4235.	1.4	358
27	Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Human Immunology, 1990, 29, 79-91.	2.4	325
28	Life Expectancy in Patients Surviving More Than 5 Years After Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2010, 28, 1011-1016.	1.6	321
29	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood, 2003, 102, 2021-2030.	1.4	320
30	Marrow Transplantation for Treatment of Aplastic Anemia. New England Journal of Medicine, 1977, 296, 61-66.	27.0	312
31	Allogeneic Bone-Marrow Transplantation. Immunological Reviews, 1983, 71, 77-102.	6.0	306
32	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. Blood, 1997, 90, 4705-4709.	1.4	303
33	MARROW TRANSPLANTATION FOR THALASSAEMIA. Lancet, The, 1982, 320, 227-229.	13.7	300
34	Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood, 2004, 104, 961-968.	1.4	300
35	Hematopoietic cell transplantationâ€“specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood, 2007, 110, 4606-4613.	1.4	292
36	Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome. Blood, 1999, 94, 1237-1247.	1.4	284

#	Article	IF	Citations
37	Predictive Factors in Chronic Graft-Versus-Host Disease in Patients with Aplastic Anemia Treated by Marrow Transplantation from HLA-Identical Siblings. Annals of Internal Medicine, 1983, 98, 461.	3.9	264
38	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. Journal of Clinical Oncology, 2008, 26, 4912-4920.	1.6	257
39	Transplantation of Marrow from an Unrelated Donor to a Patient with Acute Leukemia. New England Journal of Medicine, 1980, 303, 565-567.	27.0	251
40	Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood, 2003, 102, 2777-2785.	1.4	249
41	Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors. Journal of Clinical Oncology, 2006, 24, 444-453.	1.6	243
42	Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: A matched control study. Biology of Blood and Marrow Transplantation, 2002, 8, 512-520.	2.0	236
43	Marrow Transplantation in Thirty "Untransfused" Patients with Severe Aplastic Anemia. Annals of Internal Medicine, 1980, 92, 30-36.	3.9	230
44	Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 2004, 104, 2254-2262.	1.4	226
45	APLASTIC ANAEMIA TREATED BY MARROW TRANSPLANTATION. Lancet, The, 1972, 299, 284-289.	13.7	221
46	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. Journal of Clinical Oncology, 2013, 31, 1530-1538.	1.6	197
47	Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood, 2016, 127, 1502-1508.	1.4	174
48	Allogeneic hematopoietic cell transplantation after conditioning with 131Iâ€“anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood, 2009, 114, 5444-5453.	1.4	161
49	BONE MARROW TRANSPLANTATION: A REVIEW OF DELAYED COMPLICATIONS. British Journal of Haematology, 1984, 57, 185-208.	2.5	160
50	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003â€“2007 Versus 2013â€“2017 Cohorts. Annals of Internal Medicine, 2020, 172, 229.	3.9	157
51	Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood, 2007, 110, 2744-2748.	1.4	156
52	Graft-versus-Host Disease in Dog and Man: The Seattle Experience. Immunological Reviews, 1985, 88, 215-238.	6.0	152
53	Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood, 2004, 103, 78-84.	1.4	151
54	Stable Mixed Hematopoietic Chimerism in Dog Leukocyte Antigenâ€“Identical Littermate Dogs Given Lymph Node Irradiation Before and Pharmacologic Immunosuppression After Marrow Transplantation. Blood, 1999, 94, 1131-1136.	1.4	143

#	Article	IF	Citations
55	Allogeneic hematopoietic cell transplantation: the state of the art. Expert Review of Hematology, 2010, 3, 285-299.	2.2	142
56	Stable Mixed Hematopoietic Chimerism in Dogs Given Donor Antigen, CTLA4Ig, and 100 cGy Total Body Irradiation Before and Pharmacologic Immunosuppression After Marrow Transplant. Blood, 1999, 94, 2523-2529.	1.4	137
57	Synergism Between Mycophenolate Mofetil and Cyclosporine in Preventing Graft-Versus-Host Disease Among Lethally Irradiated Dogs Given DLA-Nonidentical Unrelated Marrow Grafts. Blood, 1998, 91, 2581-2587.	1.4	134
58	Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood, 2000, 96, 3995-3996.	1.4	122
59	Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation. Blood, 2001, 98, 3505-3512.	1.4	119
60	HISTOCOMPATIBILITY TESTING OF DOG FAMILIES WITH HIGHLY POLYMORPHIC MICROSATELLITE MARKERS1. Transplantation, 1996, 62, 876,877.	1.0	118
61	Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. Blood, 2009, 113, 2888-2894.	1.4	115
62	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. Blood, 2011, 117, 6721-6727.	1.4	113
63	Bone Marrow Transplantation in Patients with Gold-Induced Marrow Aplasia. Arthritis and Rheumatism, 1977, 20, 1043-1048.	6.7	109
64	CYCLOSPORIN A AND METHOTREXATE IN CANINE MARROW TRANSPLANTATION. Transplantation, 1982, 34, 30-35.	1.0	107
65	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood, 2009, 113, 3383-3391.	1.4	106
66	Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. British Journal of Haematology, 2005, 130, 747-751.	2.5	99
67	Comparison of ARF after myeloablative and nonmyeloablative hematopoietic cell transplantation. American Journal of Kidney Diseases, 2005, 45, 502-509.	1.9	99
68	Mesenchymal Stromal Cells: A New Tool against Graft-versus-Host Disease?. Biology of Blood and Marrow Transplantation, 2012, 18, 822-840.	2.0	99
69	RNA Splicing Modulation Selectively Impairs Leukemia Stem Cell Maintenance in Secondary Human AML. Cell Stem Cell, 2016, 19, 599-612.	11.1	97
70	Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. British Journal of Haematology, 1989, 72, 567-572.	2.5	95
71	Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica, 2011, 96, 1113-1120.	3.5	95
72	EASIX in patients with acute graft-versus-host disease: a retrospective cohort analysis. Lancet Haematology,the, 2017, 4, e414-e423.	4.6	92

#	Article	IF	Citations
73	Bismuth 213â€“labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood, 2002, 100, 318-326.	1.4	86
74	Characterization of Monoclonal Antibodies That Recognize Canine CD34. Blood, 1998, 91, 1977-1986.	1.4	85
75	The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. Biology of Blood and Marrow Transplantation, 2018, 24, 1322-1340.	2.0	85
76	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. Lancet Haematology,the, 2019, 6, e409-e418.	4.6	84
77	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood, 2014, 124, 287-295.	1.4	83
78	Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Advances, 2018, 2, 2020-2028.	5.2	81
79	Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood, 2019, 133, 2790-2799.	1.4	81
80	Hematopoietic Stem-Cell Transplantation for Treatment-Related Leukemia or Myelodysplasia. Journal of Clinical Oncology, 2001, 19, 2134-2141.	1.6	79
81	Durable engraftment of AMD3100-mobilized autologous and allogeneic peripheral-blood mononuclear cells in a canine transplantation model. Blood, 2005, 106, 4002-4008.	1.4	78
82	Transplantation of Allogeneic Peripheral Blood Stem Cells Mobilized by Recombinant Human Granulocyte Colony Stimulating Factor. Stem Cells, 1996, 14, 90-105.	3.2	77
83	Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. British Journal of Haematology, 1987, 66, 115-121.	2.5	76
84	USE OF (CA)n POLYMORPHISMS TO DETERMINE THE ORIGIN OF BLOOD CELLS AFTER ALLOGENEIC CANINE MARROW GRAFTING. Transplantation, 1994, 58, 701-706.	1.0	76
85	Hematopoietic stem cell transplantation does not restore dystrophin expression in Duchenne muscular dystrophy dogs. Blood, 2004, 104, 4311-4318.	1.4	75
86	Late effects among pediatric patients followed for nearly 4 decades after transplantation for severe aplastic anemia. Blood, 2011, 118, 1421-1428.	1.4	75
87	Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial. Haematologica, 2015, 100, 842-848.	3.5	75
88	Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. American Journal of Medicine, 1985, 78, 978-983.	1.5	73
89	Phenotyping of canine lymphoma with monoclonal antibodies directed at cell surface antigens: Classification, morphology, clinical presentation and response to chemotherapy. Hematological Oncology, 1984, 2, 151-168.	1.7	70
90	TREATMENT OF HUMAN ACUTE GRAFT-VERSUS-HOST DISEASE WITH ANTITHYMOCYTE GLOBULIN AND CYCLOSPORINE WITH OR WITHOUT METHYLPREDNISOLONE. Transplantation, 1985, 40, 162-166.	1.0	70

#	Article	IF	Citations
91	Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 694-703.	2.0	70
92	EASIX and mortality after allogeneic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 553-561.	2.4	70
93	Marrow transplant experience in children with acute lymphoblastic leukemia: An analysis of factors associated with survival, relapse, and graft-versus-host disease. Medical and Pediatric Oncology, 1985, 13, 165-172.	1.0	69
94	Improvement in rejection, engraftment rate and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anaemia. British Journal of Haematology, 1988, 69, 23-28.	2.5	69
95	Marrow grafts between canine siblings matched by serotyping and mixed leukocyte culture. Journal of Clinical Investigation, 1971, 50, 1272-1275.	8.2	67
96	Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. British Journal of Haematology, 1997, 98, 1010-1016.	2.5	66
97	Selective T-cell ablation with bismuth-213â€“labeled anti-TCRÎ±Î² as nonmyeloablative conditioning for allogeneic canine marrow transplantation. Blood, 2003, 101, 5068-5075.	1.4	65
98	Nonmyeloablative Hematopoietic Cell Transplantation. Annals of the New York Academy of Sciences, 2001, 938, 328-339.	3.8	65
99	Allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning as treatment for hematologic malignancies and inherited blood disorders. Molecular Therapy, 2006, 13, 26-41.	8.2	64
100	90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood, 2011, 118, 1132-1139.	1.4	62
101	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1418-1424.	2.0	62
102	HEMOPOIETIC GRAFTS BETWEEN DLA-IDENTICAL CANINE LITTERMATES FOLLOWING DIMETHYL MYLERAN. Transplantation, 1977, 24, 349-357.	1.0	61
103	Specific suppressor cells in graftâ€“host tolerance of HLA-identical marrow transplantation. Nature, 1981, 292, 355-357.	27.8	60
104	Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients. Blood, 2000, 96, 3991-3994.	1.4	59
105	Canine Bone Marrow-Derived Mesenchymal Stromal Cells Suppress Alloreactive Lymphocyte Proliferation in Vitro but Fail to Enhance Engraftment in Canine Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 465-475.	2.0	55
106	Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2014, 20, 1363-1368.	2.0	54
107	History of hematopoietic cell transplantation: challenges and progress. Haematologica, 2020, 105, 2716-2729.	3.5	54
108	FK-506 AND METHOTREXATE PREVENT GRAFT-VERSUS-HOST DISEASE IN DOGS GIVEN 9.2 Gy TOTAL BODY IRRADIATION AND MARROW GRAFTS FROM UNRELATED DOG LEUKOCYTE ANTIGEN-NONIDENTICAL DONORS. Transplantation, 1993, 56, 800-807.	1.0	53

#	Article	IF	Citations
109	Early and late interstitial pneumonia following human bone marrow transplantation. International Journal of Cell Cloning, 1986, 4, 107-121.	1.6	52
110	What Is the Role for Donor Natural Killer Cells after Nonmyeloablative Conditioning?. Biology of Blood and Marrow Transplantation, 2009, 15, 580-588.	2.0	52
111	Durable donor engraftment after radioimmunotherapy using Î±-emitter astatine-211â€“labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood, 2012, 119, 1130-1138.	1.4	52
112	Tolerance to Vascularized Composite Allografts in Canine Mixed Hematopoietic Chimeras. Transplantation, 2011, 92, 1301-1308.	1.0	51
113	Treosulfan-Based Conditioning and Hematopoietic Cell Transplantation for Nonmalignant Diseases: A Prospective Multicenter Trial. Biology of Blood and Marrow Transplantation, 2014, 20, 1996-2003.	2.0	51
114	Mixed Hematopoietic Chimerism after Marrow Allografts Transplantation in the Ambulatory Care Setting. Annals of the New York Academy of Sciences, 1999, 872, 372-376.	3.8	50
115	Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras1. Transplantation, 2002, 73, 1487-1493.	1.0	49
116	Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation. British Journal of Haematology, 1996, 92, 699-706.	2.5	48
117	COMBINED IMMUNOSUPPRESSION WITH CYCLOSPORINE AND METHOTREXATE IN DOGS GIVEN BONE MARROW GRAFTS FROM DLA-HAPLOIDENTICAL LITTERMATES. Transplantation, 1984, 37, 62-64.	1.0	47
118	Biodistributions, Myelosuppression, and Toxicities in Mice Treated with an Anti-CD45 Antibody Labeled with the Î±-Emitting Radionuclides Bismuth-213 or Astatine-211. Cancer Research, 2009, 69, 2408-2415.	0.9	47
119	Cytopenias after day 28 in allogeneic hematopoietic cell transplantation: impact of recipient/donor factors, transplant conditions and myelotoxic drugs. Haematologica, 2011, 96, 1838-1845.	3.5	47
120	Impact of Donor Age on Outcome after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 105-112.	2.0	47
121	The impact of donor type and ABO incompatibility on transfusion requirements after nonmyeloablative haematopoietic cell transplantation. British Journal of Haematology, 2010, 149, 101-110.	2.5	46
122	Nonmyeloablative allogeneic hematopoietic cell transplantation. Haematologica, 2016, 101, 521-530.	3.5	46
123	The transfer of antigen-specific humoral immunity from marrow donors to marrow recipients. Journal of Clinical Immunology, 1986, 6, 389-396.	3.8	45
124	Mesenchymal Stromal Cells Fail to Prevent Acute Graft-versus-Host Disease and Graft Rejection after Dog Leukocyte Antigen-Haploidentical Bone Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 214-225.	2.0	45
125	Multiâ€centre validation of the prognostic value of the haematopoietic cell transplantationâ€•specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. British Journal of Haematology, 2015, 170, 574-583.	2.5	45
126	Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. Biology of Blood and Marrow Transplantation, 2017, 23, 1669-1677.	2.0	45

#	Article	IF	Citations
127	Quasielastic light scattering study of the living human lens as a function of age. Current Eye Research, 1997, 16, 197-207.	1.5	43
128	Severe canine hereditary hemolytic anemia treated by nonmyeloablative marrow transplantation. Biology of Blood and Marrow Transplantation, 2001, 7, 14-24.	2.0	42
129	G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required. Biology of Blood and Marrow Transplantation, 2001, 7, 613-619.	2.0	42
130	Canine platelet alloimmunization: the role of donor selection. British Journal of Haematology, 1986, 63, 713-727.	2.5	41
131	An Update on Allogeneic Marrow Transplantation for Myelodysplastic Syndrome. Leukemia and Lymphoma, 1995, 17, 95-99.	1.3	41
132	The canine major histocompatibility complex. Tissue Antigens, 1983, 21, 360-373.	1.0	41
133	Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2009, 15, 4759-4768.	7.0	41
134	Outcome of Allogeneic Hematopoietic Cell Transplantation from HLA-Identical Siblings for Severe Aplastic Anemia in Patients Over 40 Years of Age. Biology of Blood and Marrow Transplantation, 2010, 16, 1411-1418.	2.0	41
135	Postgrafting immunosuppression with sirolimus and cyclosporine facilitates stable mixed hematopoietic chimerism in dogs given sublethal total body irradiation before marrow transplantation from DLA-identical littermates. Biology of Blood and Marrow Transplantation, 2003, 9, 489-495.	2.0	40
136	Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leukemia and Lymphoma, 2013, 54, 1591-1601.	1.3	40
137	Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 848-854.	2.0	40
138	Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial. Biology of Blood and Marrow Transplantation, 2010, 16, 384-394.	2.0	39
139	CURE OF MALIGNANT LYMPHOMA IN DOGS WITH PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. Transplantation, 1986, 42, 19-22.	1.0	38
140	Paroxysmal Nocturnal Haemoglobinuria and Refractory Marrow Failure Treated by Marrow Transplantation. British Journal of Haematology, 1973, 24, 743-750.	2.5	37
141	Long-term survival and cure after marrow transplantation for congenital hypoplastic anaemia (Diamond-Blackfan syndrome). British Journal of Haematology, 1993, 84, 515-520.	2.5	36
142	Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood, 2022, 139, 1694-1706.	1.4	36
143	Severe Hereditary Haemolytic Anaemia in Dogs Treated by Marrow Transplantation. British Journal of Haematology, 1976, 33, 357-362.	2.5	35
144	Marrow transplantation in hepatitis-associated aplastic anemia. American Journal of Hematology, 1984, 17, 269-278.	4.1	35

#	Article	IF	Citations
145	A pilot study of lowâ€dose cyclosporin for graftâ€versusâ€host prophylaxis in marrow transplantation. British Journal of Haematology, 1992, 80, 49-54.	2.5	35
146	Can reduced-intensity allogeneic transplantation cure older adults with AML?. Best Practice and Research in Clinical Haematology, 2007, 20, 85-90.	1.7	35
147	A Retrospective Comparison of Tacrolimus versus Cyclosporine with Methotrexate for Immunosuppression after Allogeneic Hematopoietic Cell Transplantation with Mobilized Blood Cells. Biology of Blood and Marrow Transplantation, 2011, 17, 1088-1092.	2.0	35
148	Batten's disease: failure of allogeneic bone marrow transplantation to arrest disease progression in a canine model. Clinical Genetics, 1990, 37, 264-270.	2.0	34
149	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. Haematologica, 2014, 99, 1624-1631.	3.5	33
150	CD154 Blockade and Donor-Specific Transfusions in DLA-Identical Marrow Transplantation in Dogs Conditioned with 1-Gy Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2007, 13, 164-171.	2.0	32
151	Simultaneous Transplantation of Hematopoietic Stem Cells and a Vascularized Composite Allograft Leads to Tolerance. Transplantation, 2014, 98, 131-138.	1.0	32
152	PREVENTION OF TRANSFUSION-INDUCED SENSITIZATION TO MINOR HISTOCOMPATIBILITY ANTIGENS ON DLA-IDENTICAL CANINE MARROW GRAFTS BY GAMMA IRRADIATION OF MARROW DONOR BLOOD. Transplantation, 1991, 52, 956-959.	1.0	30
153	Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission. Biology of Blood and Marrow Transplantation, 2015, 21, 373-378.	2.0	30
154	Allogeneic Marrow Transplantation. Cancer Investigation, 1984, 2, 27-38.	1.3	29
155	Allogeneic hematopoietic cell transplantation: from experimental biology to clinical care. Journal of Cancer Research and Clinical Oncology, 2005, 131, 1-13.	2.5	29
156	Hematopoietic Cell Transplantation Provides an Immune-tolerant Platform for Myoblast Transplantation in Dystrophic Dogs. Molecular Therapy, 2008, 16, 1340-1346.	8.2	29
157	MARROW TRANSPLANT STUDIES IN DOGS WITH MALIGNANT LYMPHOMA. Transplantation, 1985, 39, 499-503.	1.0	28
158	Evaluation of allogeneic transplantation in first or later minimal residual disease â€“ negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 2109-2118.	1.3	28
159	Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers, 2020, 12, 2339.	3.7	28
160	Studies of Marrow Transplantation, Chemotherapy and Cross-circulation in Canine Lymphosarcoma. Blood, 1971, 37, 349-359.	1.4	27
161	Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. Biology of Blood and Marrow Transplantation, 2013, 19, 792-798.	2.0	27
162	Canine Hemophilia and Hemopoietic Grafting. Blood, 1972, 40, 234-238.	1.4	26

#	Article	IF	Citations
163	FACILITATION OF ENGRAFTMENT OF DLA-NONIDENTICAL MARROW BY TREATMENT OF RECIPIENTS WITH MONOCLONAL ANTIBODY DIRECTED AGAINST MARROW CELLS SURVIVING RADIATION. Transplantation, 1987, 44, 607-613.	1.0	26
164	Use of multigeneration-family molecular dog leukocyte antigen typing to select a hematopoietic cell transplant donor for a dog with T-cell lymphoma. Journal of the American Veterinary Medical Association, 2006, 228, 728-732.	0.5	26
165	Stable trichimerism after marrow grafting from 2 DLA-identical canine donors and nonmyeloablative conditioning. Blood, 2007, 110, 418-423.	1.4	26
166	Immune Reactivity in Dogs With Spontaneous Malignancy 2 3. Journal of the National Cancer Institute, 1974, 53, 1049-1056.	6.3	25
167	Allogeneic Marrow Engraftment Following Whole Body Irradiation in a Patient with Leukemia. Journal of Hematotherapy and Stem Cell Research, 2001, 10, 201-208.	1.8	25
168	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. Haematologica, 2019, 104, 380-391.	3.5	25
169	HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1332-1341.	2.0	24
170	Establishment of Long-Term Tolerance to SRBC in Dogs by Recombinant Canine CTLA4-Ig. Transplantation, 2009, 88, 317-322.	1.0	23
171	Success of allogeneic marrow transplantation for children with severe aplastic anaemia. British Journal of Haematology, 2012, 158, 120-128.	2.5	23
172	Fludarabine and 2-Gy TBI is Superior to 2ÂGy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial. Biology of Blood and Marrow Transplantation, 2013, 19, 1340-1347.	2.0	23
173	CYTOTOXIC T LYMPHOCYTE ANTIGEN 4-IMMUNOGLOBULIN FUSION PROTEIN COMBINED WITH METHOTREXATE/CYCLOSPORINE AS GRAFT-VERSUS-HOST DISEASE PREVENTION IN A CANINE DOG LEUKOCYTE ANTIGEN-NONIDENTICAL MARROW TRANSPLANT MODEL1. Transplantation, 2000, 69, 450-454.	1.0	23
174	Dog leukocyte antigen-haploidentical stem cell allografts after anti-CD44 therapy and reduced-intensity conditioning in a preclinical canine model. Experimental Hematology, 2003, 31, 168-175.	0.4	22
175	Long-Term Tolerance to Kidney Allografts in a Preclinical Canine Model. Transplantation, 2007, 84, 545-547.	1.0	22
176	Bone marrow transplantation in canine GM1 gangliosidosis. Clinical Genetics, 1990, 38, 274-280.	2.0	22
177	Antagonistic and Agonistic Anti-canine CD28 Monoclonal Antibodies: Tools for Allogeneic Transplantation. Transplantation, 2011, 91, 833-840.	1.0	22
178	Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML. Leukemia, 2020, 34, 1577-1587.	7.2	22
179	THE EFFECT OF AMETHOPTERIN ON THE IMMUNE RESPONSE. Annals of the New York Academy of Sciences, 1971, 186, 467-474.	3.8	21
180	Intensified Postgrafting Immunosuppression Failed to Assure Long-Term Engraftment of Dog Leukocyte Antigen-Identical Canine Marrow Grafts After 1 Gray Total Body Irradiation. Transplantation, 2008, 85, 1023-1029.	1.0	21

#	Article	IF	Citations
181	Relapse Following Marrow Transplantation for Acute Leukemia. American Journal of Hematology, 1978, 5, 191-202.	4.1	20
182	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1582-1587.	2.0	20
183	Epitope Specificity of CD44 for Monoclonal Antibodyâ€“Dependent Facilitation of Marrow Engraftment in a Canine Model. Blood, 1998, 91, 3494-3502.	1.4	20
184	A Preclinical Canine Model for Composite Tissue Transplantation. Journal of Reconstructive Microsurgery, 2010, 26, 201-207.	1.8	19
185	Long-Term Outcomes of Patients with Persistent Indolent BÂCell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 281-287.	2.0	19
186	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. Biology of Blood and Marrow Transplantation, 2019, 25, 1045-1052.	2.0	19
187	Haemopoietic reconstitution by donor-derived myelodysplastic progenitor cells after haemopoietic stem cell transplantation. British Journal of Haematology, 1999, 105, 361-365.	2.5	18
188	Inducible Costimulator (ICOS) Up-Regulation on Activated T Cells in Chronic Graft-Versus-Host Disease After Dog Leukocyte Antigenâ€“Nonidentical Hematopoietic Cell Transplantation. Transplantation, 2013, 96, 34-41.	1.0	18
189	Î±-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After <sup›211‹/sup›At-Radioimmunotherapy for Hematopoietic Cell Transplantation. Journal of Nuclear Medicine, 2015, 56, 1766-1773.	5.0	18
190	Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. Haematologica, 2021, 106, 1599-1607.	3.5	18
191	EVIDENCE FOR AN ADDITIONAL LOCUS INVOLVED IN GRAFT-VERSUS-HOST DISEASE1. Transplantation, 1977, 24, 165-174.	1.0	17
192	Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model. Biology of Blood and Marrow Transplantation, 2001, 7, 513-516.	2.0	17
193	Using allogeneic stem cell/T-cell grafts to cure hematologic malignancies. Expert Opinion on Biological Therapy, 2008, 8, 161-179.	3.1	17
194	Immunomodulatory effects induced by cytotoxic T lymphocyte antigen 4 immunoglobulin with donor peripheral blood mononuclear cell infusion in canine major histocompatibility complexâ€“haplo-identical non-myeloablative hematopoietic cell transplantation. Cytotherapy, 2011, 13, 1269-1280.	0.7	17
195	Long-Term Tolerance to Kidney Allografts After Induced Rejection of Donor Hematopoietic Chimerism in a Preclinical Canine Model. Transplantation, 2012, 94, 562-568.	1.0	17
196	Hematopoietic Cell Transplantation for Paroxysmal Nocturnal Hemoglobinuria in the Age of Eculizumab. Biology of Blood and Marrow Transplantation, 2019, 25, 1331-1339.	2.0	17
197	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigenâ€“mismatched donors. Blood, 2020, 136, 1499-1506.	1.4	16
198	Dose rate-dependent marrow toxicity of TBI in dogs and marrow sparing effect at high dose rate by dose fractionation. Biology of Blood and Marrow Transplantation, 1999, 5, 155-161.	2.0	15

#	Article	IF	Citations
199	Long-term Tolerance Toward Haploidentical Vascularized Composite Allograft Transplantation in a Canine Model Using Bone Marrow or Mobilized Stem Cells. Transplantation, 2016, 100, e120-e127.	1.0	15
200	Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma. Blood Advances, 2017, 1, 2247-2256.	5.2	15
201	Dimethyl myleran and autologous marrow grafting for the treatment of spontaneous canine lymphoma. European Journal of Cancer, 1977, 13, 1411-1415.	0.9	14
202	A Canine Model of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 420-427.	2.0	14
203	Allogeneic Hematopoietic Cell Transplantation in the Outpatient Setting. Biology of Blood and Marrow Transplantation, 2019, 25, 2152-2159.	2.0	14
204	Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms. Haematologica, 2019, 104, 1221-1229.	3.5	14
205	Development and characterization of a canine-specific anti-CD94 (KLRD-1) monoclonal antibody. Veterinary Immunology and Immunopathology, 2019, 211, 10-18.	1.2	14
206	Dog Leukocyte Antigen-Haploidentical Stem Cell Allografts After Anti-CD44 Therapy and Nonmyeloablative Conditioning in a Preclinical Canine Model. Transplantation, 2006, 82, 332-339.	1.0	13
207	Anti-CD28 Antibody-Initiated Cytokine Storm in Canines. Transplantation Direct, 2015, 1, 1-11.	1.6	13
208	CANINE T CELLS TRANSDUCED WITH A HERPES SIMPLEX VIRUS THYMIDINE KINASE GENE. Transplantation, 1998, 66, 540-544.	1.0	13
209	Denileukin Diftitox as Prophylaxis against Graft-versus-Host Disease in the Canine Hematopoietic Cell Transplantation Model. Biology of Blood and Marrow Transplantation, 2006, 12, 899-904.	2.0	12
210	Partial Donor-Specific Tolerance to Delayed Skin Grafts After Rejection of Hematopoietic Cell Graft. Transplantation, 2006, 82, 629-637.	1.0	12
211	Hematopoietic Cell Transplantation Directly into Dystrophic Muscle Fails to Reconstitute Satellite Cells and Myofibers. Biology of Blood and Marrow Transplantation, 2007, 13, 886-888.	2.0	12
212	Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting. Bone Marrow Transplantation, 2018, 53, 1304-1310.	2.4	12
213	Delaying DLA-Haploidentical Hematopoietic Cell Transplantation after Total Body Irradiation. Biology of Blood and Marrow Transplantation, 2009, 15, 1244-1250.	2.0	11
214	Comparing High and Low Total Body Irradiation Dose Rates for Minimum-Intensity Conditioning of Dogs for Dog Leukocyte Antigenâ€“Identical Bone Marrow Grafts. Biology of Blood and Marrow Transplantation, 2013, 19, 1650-1654.	2.0	11
215	Total Body Irradiationâ€“Based versus Chemotherapy-Based Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplant. Biology of Blood and Marrow Transplantation, 2019, 25, e356-e362.	2.0	11
216	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. Bone Marrow Transplantation, 2020, 55, 172-181.	2.4	10

#	Article	IF	Citations
217	Recombinant granulocyte-macrophage colony stimulating factor followed by immunosuppressive therapy for aplastic anaemia. British Journal of Haematology, 1993, 85, 182-184.	2.5	9
218	Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiationâ€“Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 2211-2215.	2.0	9
219	ENGRAFTMENT OF DLA-NONIDENTICAL BONE MARROW FACILITATED BY RECIPIENT TREATMENT WITH ANTI-CLASS II MONOCLONAL ANTIBODY AND METHOTREXATE. Transplantation, 1987, 44, 340-345.	1.0	8
220	Adoptive immunotherapy to increase the level of donor hematopoietic chimerism after nonmyeloablative marrow transplantation for severe canine hereditary hemolytic anemia. Biology of Blood and Marrow Transplantation, 2003, 9, 674-682.	2.0	8
221	Development and in vitro characterization of canine CD40-Ig. Veterinary Immunology and Immunopathology, 2008, 123, 260-265.	1.2	8
222	Investigation of immunological approaches to enhance engraftment in a 1 Gy TBI canine hematopoietic stem cell transplantation model. Experimental Hematology, 2009, 37, 143-150.	0.4	8
223	Safety of treatment with DLA-identical or unrelated mesenchymal stromal cells in DLA-identical canine bone marrow transplantation. Chimerism, 2013, 4, 95-101.	0.7	8
224	Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 50-54.	2.0	8
225	In vitro immunoglobulin production, proliferation, and cell markers before and after antithymocyte globulin therapy in patients with aplastic anemia. American Journal of Hematology, 1987, 26, 1-15.	4.1	7
226	Allogeneic marrow grafts from donors with congenital chromosomal abnormalities in marrow cells. British Journal of Haematology, 1995, 90, 595-601.	2.5	7
227	Development of a Minor Histocompatibility Antigen Vaccine Regimen in the Canine Model of Hematopoietic Cell Transplantation. Transplantation, 2015, 99, 2083-2094.	1.0	7
228	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. Blood, 1997, 90, 4705-4709.	1.4	7
229	Implanted Right Atrial Catheters for Continuous Infusion of Solutions into Dogs. Journal of Investigative Surgery, 1993, 6, 461-467.	1.3	6
230	Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation. ILAR Journal, 2018, 59, 263-275.	1.8	6
231	Cancers after HLA-matched related bone marrow transplantation for aplastic anemia. Bone Marrow Transplantation, 2022, 57, 83-88.	2.4	6
232	Is the Leuocyte groupâ€5a antigen associated with reduced NK cell function?. Tissue Antigens, 1985, 25, 107-110.	1.0	5
233	Pharmacological Immunosuppression Reduces But Does Not Eliminate the Need for Total-Body Irradiation in Nonmyeloablative Conditioning Regimens for Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1255-1260.	2.0	5
234	Reduced-intensity Conditioning Followed by Hematopoietic Cell Transplantation for Hematologic Malignancies. , 0, , 1043-1058.		5

#	Article	IF	Citations
235	Molecular cloning and characterization of canine ICOS. Genomics, 2004, 84, 730-736.	2.9	4
236	Impact of Rituximab and Host/Donor Fc Receptor Polymorphisms after Allogeneic Hematopoietic Cell Transplantation for CD20+ B Cell Malignancies. Biology of Blood and Marrow Transplantation, 2020, 26, 1811-1818.	2.0	4
237	Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model: â€œRadioimmunotherapy to Overcome Transfusion-Induced Sensitizationâ€• Transplantation and Cellular Therapy, 2021, 27, 476.e1-476.e7.	1.2	4
238	Induction of Tolerance towards Solid Organ Allografts Using Hematopoietic Cell Transplantation in Large Animal Models. OBM Transplantation, 2018, 3, 1-1.	0.2	4
239	Detection of the Leukocyte Groupâ€5 Antigens on Normal and Leukemic Lymphocytes with the Antibodyâ€Dependent Cellâ€Mediated Cytotoxicity Assay. Tissue Antigens, 1981, 17, 174-178.	1.0	3
240	Non-myeloablative allogeneic hematopoietic cell transplantation for relapsed or refractory WaldenstrÃ¶m macroglobulinemia: evidence for a graft- versus -lymphoma effect. Haematologica, 2018, 103, e252-e255.	3.5	2
241	Developments and translational relevance for the canine haematopoietic cell transplantation preclinical model. Veterinary and Comparative Oncology, 2020, 18, 471-483.	1.8	2
242	Evolution of haematopoietic cell transplantation for canine blood disorders and a platform for solid organ transplantation. Veterinary Medicine and Science, 2021, 7, 2156-2171.	1.6	2
243	Anti-ICOS mAb Targets Pathogenic IL-17A-expressing Cells in Canine Model of Chronic GVHD. Transplantation, 2021, 105, 1008-1016.	1.0	2
244	Refractoriness to random donor platelet transfusions in patients with aplastic anaemia: a multivariate analysis of data from 264 cases. British Journal of Haematology, 1987, 66, 115-121.	2.5	2
245	Transcutaneous ultrasound-mediated gene delivery into canine livers achieves therapeutic levels of factor VIIIÂexpression. Blood Advances, 2022, 6, 3557-3568.	5.2	2
246	Utility of theÂTreatment-Related Mortality (TRM)Âscore to predict outcomes of adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Leukemia, 2022, 36, 1563-1574.	7.2	2
247	Allogeneic peripheral blood haematopoietic stem cell transplantation for the treatment of dogs with highâ€grade Bâ€cell lymphoma. Veterinary and Comparative Oncology, 2022, 20, 862-870.	1.8	2
248	Bone Marrow Transplantation for Aplastic Anaemia. British Journal of Haematology, 1975, 31, 83-88.	2.5	1
249	Evaluation of Posttransplant Methotrexate to Facilitate Engraftment in the Canine Major Histocompatibility Complex-Haploidentical Nonmyeloablative Transplant Model. Transplantation, 2010, 90, 14-22.	1.0	1
250	Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission. Bone Marrow Transplantation, 2019, 54, 1511-1514.	2.4	1
251	Postgrafting Immune Suppression Combined with Nonmyeloablative Conditioning for Transplantation of HLA-Identical Hematopoietic Cell Grafts: Results of a Phase I Study for Treatment of Immunodeficiency Disorders.. Blood, 2005, 106, 327-327.	1.4	1
252	Platelet and Red Blood Cell (RBC) Transfusion Requirements of Nonmyeloablative (NM) HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation (HCT): Influence of Genetic Disparity and ABO-Incompatibility.. Blood, 2006, 108, 2985-2985.	1.4	1

#	Article	IF	Citations
253	Addition of Astatine-211-Labeled Anti-CD45 Antibody to Total Body Irradiation (TBI) As Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model. Blood, 2016, 128, 2152-2152.	1.4	1
254	Minor Antigen Vaccine-Sensitized DLI. Transplantation Direct, 2016, 2, e71.	1.6	0
255	Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis. Transplantation and Cellular Therapy, 2021, 27, 163.e1-163.e7.	1.2	0
256	Commentary on the 1962Transfusionpaper by Don Thomas and Joe Ferrebee. Transfusion, 2022, 62, 16-21.	1.6	0
257	Marrow Allografts after Nonmyeloablative Conditioning: Effect of Cell Dose on Rejection and Degree of Donor Chimerism.. Blood, 2004, 104, 1202-1202.	1.4	0
258	Stable Mixed Hematopoietic Chimerism in Dogs Conditioned with Donor Antigen, Anti-CD154 Antibody and 100cGy TBI.. Blood, 2005, 106, 5210-5210.	1.4	0
259	DLA-Haploidentical Stem Cell Allografts after Anti-CD44 Therapy and Nonmyeloablative Conditioning: The Impact of Donor Lymphocyte Infusion (DLI), Pentostatin and Graft Composition on Donor Chimerism and Rejection.. Blood, 2005, 106, 2194-2194.	1.4	0
260	Serious Acute or Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplantation: A Comparison of Myeloablative and Non-Myeloablative Conditioning Regimens.. Blood, 2006, 108, 755-755.	1.4	0
261	Development of Chronic Lymphocytic Leukemia (CLL) Reactive Cytotoxic T Lymphocytes after Non-Myeloablative Hematopoietic Stem Cell Transplant Correlates with Anti-Leukemia Response.. Blood, 2006, 108, 413-413.	1.4	0
262	Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission. Blood, 2018, 132, 5255-5255.	1.4	0
263	CD94 Ex Vivo Cultures in a Bone Marrow Transplantation Setting. Transplantation Direct, 2020, 6, e632.	1.6	0
264	Hematopoietic Cell Transplantation for Aplastic Anemia. , 0, , 705-726.		0